Difference between revisions of "Ifosfamide (Ifex)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
|||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Nitrogen mustard, alkylator. | + | Class/mechanism: Nitrogen mustard, alkylator. Metabolites of ifosfamide interact with DNA to produce phosphotriesters and formation of DNA cross-links. Ifosfamide requires metabolic activation by microsomal liver enzymes to form its active metabolites.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Ifosfamide (Ifex) package insert]</ref><ref>[[:File:ifosfamide.pdf | Ifosfamide (Ifex) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference | <br>Extravasation: [[irritant]] or [[neutral]], depending on reference | ||
| Line 6: | Line 6: | ||
*A protective agent such as [[Mesna (Mesnex)]] should be used concurrently with ifosfamide to help prevent hemorrhagic cystitis. | *A protective agent such as [[Mesna (Mesnex)]] should be used concurrently with ifosfamide to help prevent hemorrhagic cystitis. | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is established ''(work in progress)''== | ==Diseases for which it is established ''(work in progress)''== | ||
| Line 22: | Line 22: | ||
*[[Extranodal NK- and T-cell lymphoma, nasal type]] | *[[Extranodal NK- and T-cell lymphoma, nasal type]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
| − | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Neuroblastoma]] | *[[Neuroblastoma]] | ||
| Line 41: | Line 41: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 12 | + | * 1988-12-30: Initial approval in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell [[testicular cancer]]. It should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna. ''(Based on Loehrer et al. 1986)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *1976-07-13: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2012-03-21: New additional indication and a new dosage for the treatment of [[:Category:Lymphomas|malignant lymphoma]]. | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' | *'''Brand names:''' | ||
| Line 97: | Line 100: | ||
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]] | [[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Neuroblastoma medications]] | [[Category:Neuroblastoma medications]] | ||
| Line 113: | Line 116: | ||
[[Category:FDA approved in 1988]] | [[Category:FDA approved in 1988]] | ||
| + | [[Category:EMA approved in 1976]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 01:01, 29 June 2024
General information
Class/mechanism: Nitrogen mustard, alkylator. Metabolites of ifosfamide interact with DNA to produce phosphotriesters and formation of DNA cross-links. Ifosfamide requires metabolic activation by microsomal liver enzymes to form its active metabolites.[1][2]
Route: IV
Extravasation: irritant or neutral, depending on reference
- A protective agent such as Mesna (Mesnex) should be used concurrently with ifosfamide to help prevent hemorrhagic cystitis.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
- B-cell acute lymphoblastic leukemia, Ph-positive, pediatric
- Burkitt lymphoma
- CNS lymphoma
- Cervical cancer
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- HIV-associated lymphoma
- Classical Hodgkin lymphoma
- Mantle cell lymphoma
- Neuroblastoma
- NK- and T-cell lymphoma
- Penile cancer
- Rhabdomyosarcoma
- Soft tissue sarcoma
- Small cell lung cancer
- Thymoma
- T-cell acute lymphoblastic leukemia, pediatric
Diseases for which it was used
Patient drug information
- Ifosfamide (Ifex) package insert[1]
- Ifosfamide (Ifex) patient drug information (Chemocare)[3]
- Ifosfamide (Ifex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1988-12-30: Initial approval in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. It should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna. (Based on Loehrer et al. 1986)
History of changes in EMA indication
- 1976-07-13: EURD
History of changes in PMDA indication
- 2012-03-21: New additional indication and a new dosage for the treatment of malignant lymphoma.
Also known as
- Brand names:
| Synonyms | ||||
|---|---|---|---|---|
| Alquimid | Duvaxan | Fentul | Fosfidex | Haloxan |
| Holoxan | Holoxane | Ifex | IFO Cell | Ifocris |
| Ifolem | Ifomida | Ifomide | Ifos | Ifosfamida |
| Ifoxan | IFX | Ipamide | Isophosphamide | Isoxan |
| Macdafen | Mitoxana | Tronoxal | ||
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Neutral
- Nitrogen mustards
- Burkitt lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- CNS lymphoma medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Mantle cell lymphoma medications
- Neuroblastoma medications
- NK- and T-cell lymphoma medications
- Osteosarcoma medications
- Penile cancer medications
- Rhabdomyosarcoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- T-cell acute lymphoblastic leukemia medications
- Non-small cell lung cancer medications (historic)
- FDA approved in 1988
- EMA approved in 1976
- WHO Essential Cancer Medicine